

## **Oncothermia treatment for small-cell-lung carcinoma**

**Prof. Dr. Doo Yun Lee<sup>1</sup>, Dr. Hyo Chai Paik<sup>1</sup>, Dr. Ji Won Kim<sup>1</sup>, Dr. Se Eun Jeon<sup>1</sup>, Dr. Dong Uk Kim<sup>1</sup>**

*(1) Dept of Thoracic & Cardiovascular Surgery Gangnam Severance Hospital, Yonsei University, College of Medicine, Seoul, Korea, [Hamsj@yumc.ac.kr](mailto:Hamsj@yumc.ac.kr)*

## **Oncothermia treatment for small-cell-lung carcinoma**


Prof. Dr. Doo Yun Lee<sup>1</sup>, Dr. Hyo Chai Paik<sup>1</sup>, Dr. Ji Won Kim<sup>1</sup>, Dr. Se Eun Jeon<sup>1</sup>, Dr. Dong Uk Kim<sup>1</sup>

(1) Dept of Thoracic & Cardiovascular Surgery, Gangnam Severance Hospital Yonsei University, College of Medicine, Seoul, Korea

**Introduction:** Small cell lung carcinomas (SCLC) were studied combined with various chemotherapies. This is a running study, we present only interim results. Our objective was to obtain reliable data of SCLC treatment with oncothermia.

**Method:** The treatments were provided with device EHY-2000, 60 min in all sessions, using the electrode of 30 em diameter. Data of the patients (n=14) are registered and evaluated retrospectively. The average age of patients is 64.4 y (50-77, St.Err.: 1.94), having 12/2 male/female ratio. Ten patients had only one oncotherapy cycle, while four got two cycles. Seven patients had distant metastases two of them multiple, involving their brain. Some cases are discussed in details for further considerations.

**Results:** The local clinical response is impressive, shows shrinking of tumor in ten cases while tumor growth was observed in two and no change in two cases as well. The interim results for survival shows median survival 7.5 m, (1-30) with mean survival of 10 m (St.Err.: 2.35) The Kaplan-Meier plot is shown. Case reports well demonstrate the efficacy of the oncothermia as complementary treatment for SCLC.



**Conclusion:** Oncothermia treatment has feasibility to treat SCLC. For evidences a perspective, randomized study, and the overall survival end-point is desired. The further work is in progress.